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Jaskanwal D. Sara, MBCHB,y Lilach O. Lerman, MD, PHD,z Amir Lerman, MDyC oronary vasospastic angina is a well-characterized condition in which an epicar-dial coronary vessel transiently exhibits
abnormal constriction leading to ischemia. The mech-
anism responsible for the excessive vessel contrac-
tion is believed to involve the interplay between
smooth muscle dysfunction and compromised
endothelial-mediated vessel dilation. The presence,
and most importantly the composition, of underlying
plaque may also contribute to the pathophysiology
of acute coronary syndromes in these patients.
Nevertheless, patients with vasospastic angina gener-
ally have a relatively good prognosis, though those
with concurrent atherosclerotic disease have con-
sistently been shown to have poorer outcomes,
which appear to worsen still with increasing severity
and extent of obstructive disease (1–3). How, and in
whom, coronary vasospasm inﬂuences clinical out-
comes are important questions facing our specialty
today. In their study in this issue of the Journal, Ishii
et al. (4) shed some light on these areas.SEE PAGE 1105The novelty of the Ishii et al. (4) study lies in the
unique way of categorizing participants: those with
acetylcholine (ACh)-induced vasoconstriction at the
site of organic stenosis ($75%), remote from the site
of organic stenosis, or in the absence of organic ste-
nosis. In their carefully conducted retrospective
analysis, the authors showed that patients with
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cardiovascular events (MACE) compared to those
with spasm remote to the stenosis and in the absence
of stenosis, whose prognosis did not differ from
each other; a particularly compelling result given
the small number of events observed. The same
analysis also showed use of nitrates as an indepen-
dent predictor of MACE. Furthermore, patients with
ACh-provoked spasm with concomitant signiﬁcant
organic stenosis were more likely to be young and
nondiabetic, while those with spasm without such
stenosis were more likely to be old and dyslipidemic
with a family history of ischemic heart disease. Last,
the authors showed that ST-segment elevation during
angina attacks, left anterior descending artery ste-
nosis, and multivessel spasm were positively associ-
ated with ACh-induced spasm at the site of stenosis.
It has been hypothesized that worse outcomes
in patients with vasospasm and concomitant athero-
sclerotic disease may arise from greater vessel oc-
clusion leading to more severe myocardial ischemia
and/or ventricular arrhythmia. Alternatively, the
adverse outcomes in this group may be more closely
linked to the presence of more advanced athero-
sclerotic disease, while the vasospasm’s role may be
to identify vulnerable active lesions that are prone
to rupture and lead to thrombotic events. The retro-
spective observational design of the Ishii et al. (4)
study makes determining any causal association be-
tween vasospasm and coronary events challenging.
Prospective studies employing continuous remote
monitoring may allow for the identiﬁcation of
ischemic and/or ventricular arrhythmia episodes in
patients with spasm at the site of as opposed to
remote from organic stenosis, which would help to
establish the role of organic stenosis site-related
spasm in leading to MACE in this population. Better
still, follow-up angiograms with intravascular imag-
ing would allow investigators to relate the site of
acute coronary events (the target lesion) to the site
of ACh-induced spasm (the active lesion). This
FIGURE 1 Approach to Investigating Patients at Coronary Angiography
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After identifying a ﬂow-limiting lesion, pharmacologic provocation with acetylcholine distinguishes hyperactive lesions, with impaired
endothelial-dependent vasodilation only, from nonreactive lesions, with endothelial dysfunction and impaired smooth muscle-mediated
constriction. Hyperactive lesions may be associated with vulnerable plaque characteristics and an increased risk of coronary events. ACS¼ acute
coronary syndrome(s).
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1117approach would help establish the role of a hyper-
active lesion/vulnerable plaque combination for
which there is increasing evidence, including the
association between inducible vasoconstriction to
acetylcholine as a marker for endothelial dysfunction
and plaque progression (5), vulnerable plaque char-
acteristics (6,7), and increased platelet activation and
adhesion (8). If indeed organic stenosis site-related
spasm is shown to be associated with thrombotic
target-lesions, further studies evaluating these active
lesions using intravascular ultrasound and optical
coherence tomography in stable patients would be
critical to identify vulnerable plaque characteristics
(Figure 1), which would then pave the way for better
risk stratiﬁcation.
Currently, patients with vasospastic angina should
be treated with anti-atherosclerotic and anti-platelet
therapy, not only for the abovementioned reasons
but also because ACh-induced vasospasm is almost
always associated with some degree of atherosclerosis(9). As for the vasospasm itself? Calcium-channel
blockers and nitrates have formed the cornerstone of
symptom management, and while some observational
studies have shown a survival beneﬁt in patients
taking calcium-channel blockers (3,10) potentially
through limiting vessel occlusion, other studies have
failed to replicate these ﬁndings. The only random-
ized controlled trial evaluating the role of calcium-
channel blockers in patients with vasospastic angina
investigated a small number of patients across a
4-week follow-up period and focused on frequency
of anginal episodes as the primary endpoint (11).
How these agents fare in mitigating MACE in pa-
tients with vasospastic angina needs to be clariﬁed.
Furthermore, because nitrates also limit vasospasm,
they may similarly inﬂuence the incidence of events
in these patients. Interestingly, however, Ishii et al.
(4) showed that use of nitrates was independently
associated with a worse prognosis. Other observa-
tional studies have demonstrated similar ﬁndings
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treatment with nitrates may be more vulnerable to
adverse events, or this association may reﬂect a true
facet of treatment with nitrates. These questions
are best answered with larger clinical trials evalu-
ating the efﬁcacy of these agents in patients with
ACh-inducible spasm. These trials would also help
determine which additional pharmacotherapy is
required to negate the increased risk observed in
patients with ACh-induced spasm at the site of
organic stenosis.
Interestingly, the authors showed that vasospastic
angina patients with stenosis were more likely to be
young and nondiabetic, while those without stenosis
were more likely to have traditional cardiovascular
risk factors such as old age, dyslipidemia, and a
family history of ischemic heart disease. The con-
trasting clinical features between the groups suggest
the predominance of different pathophysiological
mechanisms in each group. Patients without signiﬁ-
cant stenosis and ACh-induced spasm had traditional
cardiovascular risk factors, which often correlate with
endothelial dysfunction, implicating the potential
role of impaired endothelium-mediated vasodilation.
Those with stenosis lacked traditional cardiovascular
risk factors and may represent a group with primarily
smooth muscle reactivity, which typically does not
correlate with cardiovascular risk factors. Further
studies establishing the relative importance of theendothelium and smooth muscle in these patients, by
making use of other pharmacological agents such as
nitroglycerin, would help clarify the precise mecha-
nisms behind the vasospasm. Moreover, the authors
also identiﬁed potentially important comparison
groups consisting of symptomatic patients without
ACh-induced spasm with and without organic steno-
sis. Critically, however, follow-up informationwas not
provided on these individuals. A proportion of these
patients may have coronary microvascular disease and
may thus still be at risk of cardiovascular events
(13,14). Further studies establishing the cause of
symptoms, by additionally interrogating the micro-
circulation, and identifying the optimal management
of this group are therefore required.
There is much work to be done in order to identify
patients with high-risk lesions that are prone to
cardiovascular events. The current study supports
the concept of the active lesion/vulnerable plaque
combination, and calls for future studies that go
beyond the anatomy to clarify the mechanisms
behind the vasospasm and cardiovascular events in
patients with vasospastic angina.
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